Cargando…

Acute Myeloid Leukemia in the Elderly Patient: New Strategies

Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. I...

Descripción completa

Detalles Bibliográficos
Autor principal: Thomas, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837938/
https://www.ncbi.nlm.nih.gov/pubmed/27182475
http://dx.doi.org/10.1007/s40487-015-0006-7
_version_ 1782427931030585344
author Thomas, Xavier
author_facet Thomas, Xavier
author_sort Thomas, Xavier
collection PubMed
description Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40487-015-0006-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4837938
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-48379382016-05-11 Acute Myeloid Leukemia in the Elderly Patient: New Strategies Thomas, Xavier Rare Cancers Ther Review Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40487-015-0006-7) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-07-04 2015 /pmc/articles/PMC4837938/ /pubmed/27182475 http://dx.doi.org/10.1007/s40487-015-0006-7 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Review
Thomas, Xavier
Acute Myeloid Leukemia in the Elderly Patient: New Strategies
title Acute Myeloid Leukemia in the Elderly Patient: New Strategies
title_full Acute Myeloid Leukemia in the Elderly Patient: New Strategies
title_fullStr Acute Myeloid Leukemia in the Elderly Patient: New Strategies
title_full_unstemmed Acute Myeloid Leukemia in the Elderly Patient: New Strategies
title_short Acute Myeloid Leukemia in the Elderly Patient: New Strategies
title_sort acute myeloid leukemia in the elderly patient: new strategies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837938/
https://www.ncbi.nlm.nih.gov/pubmed/27182475
http://dx.doi.org/10.1007/s40487-015-0006-7
work_keys_str_mv AT thomasxavier acutemyeloidleukemiaintheelderlypatientnewstrategies